AbbVie
ABBV
#25
Rank
NZ$942.58 B
Marketcap
NZ$533.25
Share price
-0.59%
Change (1 day)
28.87%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2026 (TTM): NZ$22.51 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$66.01 Billion. In 2025 the company made an earning of NZ$12.01 Billion, an increase over its 2024 earnings that were of NZ$6.76 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$22.51 B87.45%
2025 NZ$12.01 B77.53%
2024 NZ$6.76 B-40.54%
2023 NZ$11.38 B-53.62%
2022 NZ$24.54 B3.76%
2021 NZ$23.65 B282.25%
2020 NZ$6.18 B-59.67%
2019 NZ$15.34 B62.13%
2018 NZ$9.46 B-32.74%
2017 NZ$14.07 B-1.99%
2016 NZ$14.35 B18.65%
2015 NZ$12.10 B180.5%
2014 NZ$4.31 B-55.57%
2013 NZ$9.71 B-6.86%
2012 NZ$10.42 B56.05%
2011 NZ$6.68 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$12.68 B-45.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$63.31 B 171.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$20.12 B-13.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$0.81 B-96.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
-NZ$4.62 Billion-119.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$20.63 B-11.57%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$27.47 B 17.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$13.02 B-44.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$1.57 B-93.27%๐Ÿ‡บ๐Ÿ‡ธ USA